Actively Recruiting
Albumin and Crystalloid Administration in Septic Shock
Led by Asan Medical Center · Updated on 2025-07-02
2426
Participants Needed
1
Research Sites
258 weeks
Total Duration
On this page
Sponsors
A
Asan Medical Center
Lead Sponsor
S
Samsung Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.
CONDITIONS
Official Title
Albumin and Crystalloid Administration in Septic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older who visit an emergency department and are suspected of having sepsis with shock
- Shock defined as low blood pressure (mean arterial pressure < 65 or systolic blood pressure < 80) and tissue hypoperfusion such as an initial serum lactate level ≥ 4 mmol/dL
You will not qualify if you...
- Patients transferred from another hospital after initial fluid administration
- Patients with limitations on treatment such as do-not-resuscitate orders
- Patients with life expectancy less than 28 days due to severe illness or advanced cancer and those in palliative care with life expectancy less than 6 months
- Patients who have received albumin before enrollment
- Patients with known allergy to albumin
- Patients with conditions where albumin may be harmful, including pulmonary edema, congestive heart failure, or traumatic brain injury
- Women who are breastfeeding
- Patients who do not voluntarily consent to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
Research Team
S
Sang-Min Kim, Dr.
CONTACT
W
Won Young Kim, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here